A Multicenter, Open Label, Single-Treatment, Single-Period, Single Dose, Pilot Study to Evaluate the Bioavailability of ZOLADEX (Goserelin Acetate Implant injection BP) 3.6 mg in Pre- and/or Peri-menopausal women with Advanced Breast Cancer.

ONG GROVE PHARMACEUTICALS LLC0 个研究点目标入组 0 人开始时间: 待定最近更新: 2021年11月24日

试验速览

阶段: 未知
状态: 尚未招募
发起方

研究概览入排标准研究者记录与标识符相似试验

研究概览

简要总结

暂无简介。

研究设计

研究类型: Ba/be

入排标准

入选标准

•1. Pre- and/or peri-menopausal female patients age 18 to 50 years of age (both inclusive) with confirmed diagnosis of advanced breast cancer (stage III or stage IV or recurrent metastatic disease) for whom palliative endocrine treatment is indicated and who are eligible to start treatment with goserelin.
•2. BMI 18 to 31 kg per meter square (both inclusive), with minimum weight being 45 kg.
•3. Patients must be able to understand the investigational nature of this study and to give written informed consent prior to the participation in the trial.
•4. Eastern Cooperative Oncology Group (ECOG) performance status less than 2.
•5. Patients with life expectancy of at least 6 months.
•6. Able to comply with study requirement in the opinion of the Investigator.
•7. Non-smoker defined as non-smoker for at least 6 months (i.e. subject has not smoked
•or used any tobacco products for the 6 months prior to the screening visit); Patients must test negative on nicotine/cotinine screen at Screening and Check-In.
•8. Patients must not have taken any anti-androgens, estrogen, antiestrogen, selective
•estrogen receptor modulators, aromatase inhibitors or hormonal forms of contraception within past one month of screening. Patient may have had recent use of oral contraceptive pills but these must be discontinued 30 days prior to dosing.
•9. Women of child bearing potential (WOCBP) must not be pregnant or breastfeeding (as documented by a negative serum pregnancy test at screening and negative urine pregnancy test at baseline).
•10. Women of child bearing potential (WOCBP) must use an acceptable and effective non-hormonal method of avoiding pregnancy, starting at least four weeks before the study drug administration and up to 12 weeks after the study drug administration. Cessation of birth control after this point should be discussed with the responsible physician. For this study, acceptable and effective methods of contraception include:
•-Tubal sterilization (tubal ligation performed more than one month before Study Day 1; transcervical tubal occlusion procedure performed more than six months before Study Day 1)
•-Barrier method (cervical cap, diaphragm, contraceptive sponge, vaginal spermicide, female condom, or male condom)
•-Two barrier methods used together (cervical cap, diaphragm, contraceptive sponge, or vaginal spermicide plus a male or female condom)
•-Absolute sexual abstinence (no sexual intercourse or genital contact with a male
•partner). If the patient becomes sexually active during the study, then she is required to use a double barrier method of contraception.

排除标准

•1. Patients who are not able to provide written informed consent.
•2. Patients who are menopausal
•3. Patients who are pregnant (based on positive pregnancy test at screening or baseline) or breastfeeding.
•4. Concurrent malignancy or history of malignancy within last 5 years before screening except curatively treated carcinoma in situ of the uterine cervix or basal cell carcinoma of the skin.
•5. Patients with a clinically significant medical condition other than advanced breast
•cancer including but not limited to respiratory, renal, hepatic, hematological,
•gastrointestinal, endocrine, gynecological, cardiovascular, neurological or psychiatric
•disease, alcohol or substance abuse, or any other condition that may affect the patient health or the outcome of the trial as judged by the investigator.
•6. Presence of clinically significant physical exam, laboratory, medical history, ECG or echocardiogram findings that in the opinion of the Investigator may interfere with trial conduct, patient safety, or interpretation of results.
•7. Patients with a known hypersensitivity to GnRH, GnRH-agonist analogues or any of the components in IMP.
•8. Patients who are already receiving and/or previously received goserelin.
•9. Patients receiving anticoagulation medications.
•10. Patients with uncontrolled diabetes mellitus (HbA1c greater than 8% as per ADA).
•11. Patients with confirmed signs or symptoms related to cerebral metastasis or radiographically-confirmed brain metastasis.
•12. Uncontrolled hypertension (systolic blood pressure [BP] greater than 140 or diastolic BP
•greater than 90mm Hg) or uncontrolled cardiac arrhythmias. (Patients with hypertension controlled by antihypertensive therapies are eligible).
•13. Patients with a QTc greater than 450 ms on the ECG at screening or with a personal or family history of long QT syndrome (QTc greater than 450 ms).
•14. History of clinically significant cardiovascular disorder or presence of significant risk factor for coronary artery disease
•15. Use of any recreational drugs (cocaine, amphetamines, barbiturates, benzodiazepines, cannabinoids and morphine) or history of drug or alcohol abuse within the past 1 year, as judged by the Investigator, or a positive result on the urine drug/alcohol screen which is not consistent with current medical treatment.
•16. Concomitant use of medicinal products known to prolong the QT interval or medicinal products able to induce Torsade de pointes such as class IA (e.g. quinidine, disopyramide) or class III (e.g. amiodarone, sotalol, dofetilide, ibutilide) antiarrhythmic medicinal products, methadone, moxifloxacin, antipsychotics.
•17. A positive hepatitis screen including hepatitis B surface antigen or HCV antibodies.
•18. Patients who test positive for HIV and/or syphilis.
•19. The receipt of an investigational product, or participation in a drug research study
•within a period of 30 days prior screening or 5 half-lives within the last dose of investigational product, whichever is longer. Current use of any drugs that are known
•to interfere with goserelin metabolism or to cause a drug-drug interaction.
•20. Donation / loss of blood/plasma or blood product (without replenishment) (1 unit or
•350 mL) within 90 days prior to receiving the first dose of study medicine.
•21. Patients who are smokers or toba

研究者

发起方

ONG GROVE PHARMACEUTICALS LLC

相似试验

招募中

1 期

ate-onset sepsis in term and pre-term neonates and infants up to 3 months of ageate-onset sepsis (LOS) in term and pre-term neonates andinfants up to 3 months of age.MedDRA version: 20.1Level: LLTClassification code 10053598Term: Late onset neonatal sepsisSystem Organ Class: 100000004862

EUCTR2022-001837-35-LTBasilea Pharmaceutica International Ltd, Allschwil15

进行中（未招募）

1 期

EUCTR2022-001837-35-PLBasilea Pharmaceutica International Ltd, Allschwil15

进行中（未招募）

1 期

EUCTR2022-001837-35-SKBasilea Pharmaceutica International Ltd, Allschwil8

进行中（未招募）

1 期

ate-onset sepsis in term and pre-term neonates and infants up to 3 months of age

EUCTR2022-001837-35-DEBasilea Pharmaceutica International Ltd, Allschwil8

招募中

1 期

ate-onset sepsis in term and pre-term neonates and infants up to 3 months of age

EUCTR2022-001837-35-BGBasilea Pharmaceutica International Ltd, Allschwil8